PSTM Abstract Supplement in Phase 3 development for treatment of moderate-to-severe pain in medically-supervised settings, such as outpatient or ambulatory surgery. Sublingual sufentanil appears wellsuited for short duration acute pain management because it acts rapidly (plasma-CNS equilibration time of 6 minutes), does not require an invasive route of delivery and possess a predictable off-set, in part due to lack of active metabolites. The primary objective of this study was to compare the efficacy and safety of the ST to placebo tablet (PT) for the management of moderate-to-severe acute pain following typical outpatient abdominal surgeries.
METHODS:
The study was multicenter, randomized and placebo-controlled for up to 48 hours in adult patients undergoing the following outpatient abdominal surgical procedures: abdominoplasty, open tension-free inguinal hernioplasty or laparoscopic abdominal surgery. Following IRB approval and patient informed consent, approximately 180 patients who met all inclusion and none of the exclusion criteria were randomly assigned at a 2:1 ratio to treatment with ST or PT. Efficacy was assessed by patient reports of pain intensity on an 11-point numerical rating scale (0 = no pain, and 10 = worst possible pain) and a five-point pain relief scale (0 = no relief, 4 = complete relief). The primary efficacy variable was the summed pain intensity difference to baseline over the 12-hour study period (SPID12). Safety was assessed via periodic measurement of vital signs, continuous monitoring of oxygen saturation, spontaneously reported adverse events (AEs) and the use of concomitant medications.
RESULTS:
A total of 161 (107 ST and 54 PT) patients were randomized and received study drug. Average patient age was 41 years, 68% were female and approximately 50% had undergone abdominoplasty surgery. Statistically significant SPID12 differences were observed in favor of ST over PT (25.8 vs. 13.1; p<0.001) for the entire cohort, demonstrating superiority of sublingual sufentanil 30mcg for management of acute post-operative pain. Subgroup analysis by surgery type, despite much smaller sample sizes, also yielded significantly higher scores for ST over PT for abdominoplasty patients (30.8 vs 17.6; p=0.001). Most AEs were mild to moderate in severity with nausea and headache as the most common across both treatment arms.
DISCUSSION/CONCLUSION:
The sufentanil sublingual 30 mcg tablet has shown benefit over placebo across a range of surgical procedures as a non-invasive analgesic modality requiring short-term treatment of acute moderateto-severe pain. 1-3 However, variations in postoperative outcomes for minority populations remain understudied. 4 The objectives of this study are to evaluate racial and ethnic variations in complications and patient-reported outcomes (PROs) following breast reconstruction.
Racial and Ethnic Variations in

MaTERIaLS aND METHODS:
The Mastectomy Reconstruction Outcomes Consortium is an 11 center, prospective cohort study assessing clinical and patient-reported outcomes following autologous and implant-based breast reconstruction. Race and ethnicity data were available by self-report and medical records. Complications (major or any) and reconstructive failures at one-year post-reconstruction were recorded. PRO measures included BREAST-Q subscales for satisfaction with breasts, sexual, psychosocial, and physical well-being, as well as the PROMIS subscale for physical functioning. Mixedeffects logistic regression models were used to assess clinical outcomes and mixed-effects linear models were used to evaluate patient reported outcomes at one-year postoperatively.
RESULTS:
A total of 2,476 women with known race and ethnicity information had one-year follow-up data, including 2,058 (83.1%) White, 146 (5.9%) Black, 133 (5.4%) Hispanic or Latino, and 139 (5.6%) patients from other minority groups. Patient age, body mass index, education, household income, laterality, diabetes status, and indication for mastectomy differed by race and ethnicity. Clinical outcomes were available for all women, but PROs at one-year were completed by 1,456 (response rate = 74.1%) White, 65 (47.4%) Black, 74 (56.9%) Hispanic or Latino, and 80 (59.3%) patients from other minority groups. To account for differential non-response rates across race groups, all PRO analyses were weighted by the inverse of the response probability, in addition to adjusting for baseline covariates. At one-year postoperatively, no differences were noted in clinical outcomes by race or ethnicity, but black women experienced higher psychosocial (P=.001) and sexual well-being (P=.004) relative to white women.
CONCLUSION:
Despite a growing body of literature identifying disparities in clinical outcomes for minority populations, 5 differences in complication and failures rates across race following breast reconstruction were not significant. Furthermore, the data suggest that black women experienced a greater increase in psychosocial and sexual well-being from undergoing reconstruction. In the context of a healthcare system increasingly focused on clinical and patient-report outcomes, future studies are needed to investigate loss to follow-up among underserved populations undergoing breast reconstruction. 
